VALIENT: Phase 1 Clinical Trial of VorAsidenib in Combination With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

This phase I study will evaluate the safety and tolerability of vorasidenib in combination with lomustine and determine the recommended combination dose (RCD) of vorasidenib in adults with recurrent IDH1- or IDH2-mutant glioma. The study consists of a dose de-escalation phase followed by a dose-expansion cohort to further evaluate safety and preliminary clinical activity.

开始日期2026-11-30

申办/合作机构

University of Pittsburgh

[+1]

NCT07811297

/ Not yet recruiting临床1/2期

Phase 1b/2a Clinical Study of Catequentinib Hydrochloride (AL3818) Monotherapy or Combining Therapy With Other Anti-tumor Agents in Advanced, Metastatic Endometrial, Low Grade Serous Ovarian Cancer (LGSOC), STS or GBM Cancers

This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors. The phase 1b part will identify doses that can be given safely based on side effects during the first treatment cycle. The phase 2a part will estimate whether the treatments shrink non-brain tumors or keep glioblastoma from worsening for at least 6 months.
The study is open label, which means participants and study investigators will know which treatment is given. Tumor response will be assessed with RECIST version 1.1. The study will also evaluate how the investigational drugs move through the body, the duration of tumor response, progression-free survival, overall survival, and treatment safety.

开始日期2026-09-01

申办/合作机构

Advenchen Laboratories LLC

NCT07632209

/ Not yet recruiting临床2期IIT

A Single-arm, Phase II Interventional Study to Evaluate the Efficacy and Safety of Lomustine Combined With Anlotinib in Patients With Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Further Lines of Treatment

This single-arm phase II study aims to evaluate the efficacy and safety of lomustine combined with anlotinib in patients with extensive-stage small cell lung cancer resistant to second-line and above systemic treatment.

开始日期2026-06-01

申办/合作机构

上海市肺科医院

100 项与洛莫司汀相关的临床结果

登录后查看更多信息

100 项与洛莫司汀相关的转化医学

登录后查看更多信息

100 项与洛莫司汀相关的专利（医药）

登录后查看更多信息

2,833

项与洛莫司汀相关的文献（医药）

2026-12-01·FUNCTIONAL & INTEGRATIVE GENOMICS

Comprehensive study of the tumor immune microenvironment and the prognostic significance of reticulocalbin-1: a pan-cancer analysis

Article

作者: Liu, JunZhi ; Wang, JiWei ; Sun, QingYuan ; Yang, Ning ; Wang, Xinyu ; Huang, Bin ; Zhao, JiangLi ; Xue, ZhiWei ; Liu, XuChen ; Peng, ShuJie ; Li, Chao

Reticulocalbin-1 (RCN1), an endoplasmic reticulum (ER)-related gene, demonstrates critical regulatory functions in cellular growth. RCN1 has been previously revealed to be closely associated with initiation, metastasis and chemosensitivity in some tumors. However, the prognostic significance of RCN1 and its influence on the cancer immune microenvironment remains unclear. By leveraging multi-omics data from TCGA and GEO, this study delineated the expression profile of RCN1 across various human malignancies and normal tissues. Analysis of RCN1 expression in correlation with tumor immune microenvironment characteristics was performed using CIBERSORT and ssGSEA. Pan-cancer prognostic value was assessed via multiple survival models. In glioma, immunohistochemistry, co-culture, and qPCR were utilized to further investigate the role of RCN1 in tumor immunity and prognosis. Drug-specific responses to RCN1 expression were probed for cisplatin, irinotecan, carmustine and lomustine, which are the common chemotherapeutic agents used in glioma clinical treatment. The results indicate that RCN1 is a key gene with the potential to promote the progression of multiple tumors and is closely associated with tumor immune response, particularly macrophage activation. In glioma, overexpression of RCN1 promotes tumor proliferation and indicates poor prognosis, and is closely related to endoplasmic reticulum stress. Knockdown of RCN1 enhances the chemotherapeutic efficacy of carmustine and lomustine. In conclusion, our research positioned RCN1 as an important oncogene from a pan-cancer perspective and validated its role in glioma. In particular, RCN1 is closely associated with the immune microenvironment and endoplasmic reticulum stress during tumorigenesis. In addition, RCN1 has broad prospects in guiding tumor chemotherapy pending physiological in vivo validation.

2026-11-01·ANALYTICA CHIMICA ACTA

Development of a monospecific monoclonal antibody and a homogeneous chemiluminescence immunoassay for selective detection of “stopped” lomefloxacin

Article

作者: Qin, Danfeng ; Li, Zizhe ; Wen, Kai ; Wang, Zhanhui ; Pan, Yantong ; He, Tong ; Liu, Gelin

BACKGROUND:

Lomefloxacin (LOM) has been stopped from use in food-producing animals in China and is regulated at lower maximum residue limits than permitted fluoroquinolones (FQs). However, the highly conserved FQ scaffold makes conventional broad-specificity antibodies unable to discriminate LOM from related analogues, leading to frequent false-positive results in immunoassays. Therefore, the development of monospecific antibodies that selectively recognize LOM and high-throughput screening methods for monitoring LOM residues remains urgently needed.

RESULTS:

Here, a unique epitope-exposed antigen design was combined with specificity-oriented hybridoma screening to direct antibody generation toward the characteristic structural features of LOM. The obtained mAb17D9 was the first antibody with monospecificity toward LOM, exhibiting an icELISA IC₅₀ of 0.164 μg/L and cross-reactivities below 1% against 16 structurally related FQs. SPR analysis further confirmed its preferential binding to LOM, with an affinity 27.3- to 15024.0-fold higher than that for FQ analogues. Structural feature analysis and molecular interaction analysis indicated that this monospecific recognition mainly originated from preferential interactions between mAb17D9 and the characteristic groups of LOM at the N1, C7, and C8 positions. Based on mAb17D9, a homogeneous chemiluminescence immunoassay (HCLIA) was established for the rapid screening of LOM residues, achieving limits of detection of 0.077-0.136 μg/kg in various animal-derived food matrices.

SIGNIFICANCE:

This study offers a viable solution for the selective detection of a target analyte among structurally similar drugs by providing a broadly applicable strategy for generating monospecific antibodies. The established HCLIA provides a robust tool for monitoring LOM residues in animal-derived foods, enhancing surveillance efficiency and strengthening food safety assurance.

2026-10-03·CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY

Quantifying Nitrosoureas: Comprehensive Insights into Analytical Techniques Transforming Cancer Research

Review

作者: Qader, Aryan Fathulla ; Salih, Musher Ismael ; Ali, Hoshyar Saadi ; Anwar Omer, Rebaz ; Barzani, Hemn A. H. ; Sulaiman, Seerwan Hamadameen

Nitrosoureas (NUs) are a crucial class of antineoplastic agents widely used in chemotherapy to treat various malignancies, including brain tumors, lymphomas, and metastatic cancers. Over the past decade, the clinical application of NU-based chemotherapeutic drugs has expanded significantly, leading to their administration in a larger cohort of cancer patients. Despite their therapeutic efficacy, NUs exhibit high cytotoxicity, often resulting in severe adverse effects, including myelosuppression, nephrotoxicity, and pulmonary fibrosis. Given these challenges, developing reliable, sensitive, and precise analytical techniques is essential for accurately quantifying and monitoring these drugs in biological systems. This review provides a comprehensive overview of the analytical methodologies employed over the past forty years for the detection and quantification of five widely used nitrosourea-based anticancer drugs-carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU), nimustine (NMT), and fotemustine (FM)-along with their metabolites. The discussion encompasses spectroscopic, chromatographic (liquid chromatography, gas chromatography, and high-performance liquid chromatography), and electroanalytical techniques utilized for the analysis of these compounds in various matrices, including biological fluids (plasma, urine, and tissue samples), pharmaceutical formulations, and environmental samples. Furthermore, advancements in hybrid analytical techniques and their potential in enhancing the selectivity and sensitivity of NU detection are explored. This review aims to provide insights into the evolution of analytical approaches for nitrosourea-based drugs, highlighting their applications in pharmacokinetics, therapeutic drug monitoring, and environmental surveillance.

184

项与洛莫司汀相关的新闻（医药）

2026-10-18

·类器官分晓

胶质瘤：取材窗口只有 3 小时（下）

上期回顾｜一、疾病与市场背景：一个「手术采样即终点」的瘤种 / 二、亚型与分子分型全景：逐亚型点出建立难点 / 三、样本来源与取材策略：真正卡住产能的 3 小时 / 四、分亚型建立配方：五条路线，各配一套认证话术 / 五、建立成功认证标准：通用五件套 + 胶质瘤专属加项本篇承接上期。未读上期可在公众号历史消息中查看。六、药敏检测与 Panel 设计 6.1 三层 Panel 层级药物判读指标依据层 1 一线锚点替莫唑胺（TMZ）、洛莫司汀、贝伐珠单抗（复发）IC50 + AUC 双指标；TMZ 的 AUC 参考区间 200–600，MGMT 甲基化者 AUC 更低（更敏感） Golebwska 团队口径；与临床试验高度一致层 2 分型靶向 vorasidenib / IDH 双靶点抑制剂（IDH 突变）；vebreltinib 等 MET 抑制剂（MET 扩增）；lazertinib（第三代 EGFR-TKI）；regorafenib；pexidartinib（CSF1R） IC50；与分子靶点状态的相关性 IDH1 突变类器官对 vorasidenib 敏感性显著高于野生型（Current Medicinal Chemistry 2026）；lazertinib 在 TMZ 耐药 GBO 中有效（Cell Rep Med 2026）层 3 机制发现蛋白酶体抑制剂（carfilzomib/bortezomib/ixazomib）、HDAC 抑制剂（panobinostat/romidepsin）；FDA 药物库 166 药初筛 2.5 μM 单浓度 72 h；仅上述 4 药达到 Cmax/IC50 > 1 npj Precision Oncology 2026（HTS + RNAi 验证 PSMB5、HDAC1/2）放疗响应（加项） 8 Gy γ 照射（第 0 天与第 4 天各一次）相对活力 IDH1 突变类器官活力显著下降，野生型无显著变化 6.2 一致性数据（样本量必须随数字一起引用）研究样本量一致性结论 KAIST / 忠南大学（Cell Rep Med 2026-06-12）55 例/59 样本 → 36 株；18 株进入临床相关性分析（含 PFS/OS 终点）GBO-DST 与 TMZ 临床响应 100% 一致；同期 MGMT 甲基化仅 77.8%；IC50 低者 PFS/OS 显著更长（p<0.05）；新诊断与复发两组均成立 SNO 2025 TMOD-07（同一体系）19 株中 10 株进入 TMZ 评估 3 株在 50 μM TMZ 下存活率 <50%；PFS 按 GBO-DST 分层 p=0.011 IPTO 前瞻队列（Cell Stem Cell 2025）35 例 GBM 准确预测 TMZ 响应，优于 MGMT 状态；3 周出结果 AI4Med（ASCO 2026，JCO 2026;44(16_suppl):e14086） 1,406 细胞系 / 481 化合物（模型层）+ 类器官实体验证 top-5 药敏预测准确率 97%、top-10 85% GlioME（Bioactive Materials 2025）n=1 个案 IDH 突变复发 4 级星形细胞瘤、MET 扩增患者，vebreltinib 用药 2 个月 MRI 明显缩小，达 RANO 2.0 CR。单例，不得作为一致性率引用判断判读流程与窗口：2.5 μM 单浓度 72 h 初筛 → 剂量-反应 8 点复筛 → IC50/AUC 双指标报告。脑肿瘤类器官药测的报告周期全行业口径为 2–4 周——这个窗口是临床药敏能不能落地的硬约束，也是自动化建库设备（5–7 天出微球、7–9 天出报告）的卖点所在。判断一个必须承认的局限：复发胶质母细胞瘤（rGBM）综述明确指出，GBO 路线存在 20%–30% 培养失败率，且 AI 模型泛化性不足。对临床客户的承诺必须写成「建库成功后 X 天出报告」，而不是「送样后 X 天出报告」。七、产业化与商业化：谁在买，按什么价买 7.1 监管路线图（2021–2026）中国：2021-11 CDE 在《基因治疗产品非临床研究与评价技术指导原则（试行）》中首次将类器官列入替代方法；2024-10《模型引导的罕见病药物研发技术指导原则》征求意见，2025-07 配套正式文件明确纳入类器官与器官芯片；2026-07-07 CDE 发布《推进新方法（NAMs）研究和应用试点计划（「先锋计划」）》申报通知，2026-09-28 正式发布（通告 2026 年第 46 号），设两类申请情形（围绕具体药物的应用 / 围绕新方法的方法学验证），每次申请只能包含一个应用场景（COU）；2026-08-31 CDE《单克隆抗体动物试验减少或替代指导原则（征求意见稿）》明确将类器官/器官芯片纳入**证据权重（WoE）**框架。行政法规层面，2025-10 国务院令第 818 号《生物医学新技术临床研究和临床转化应用管理条例》2026-05 施行；2025-05《人源类器官研究伦理指引》首次构建全过程伦理治理框架。收费端，2026-08-14 国家医保局《检验类医疗服务价格项目立项指南（试行）》设「肿瘤组织类器官培养费」（计价单位「次」）与「肿瘤类器官药物敏感性检测费」（定性/定量两子项，按「每例标本·每种药物」计费），价格构成明确纳入人工智能辅助操作与数据上传成本，并延续「缺数减收」（未上传数据每项减收 ≥10%，上限 5 元）。海外：FDA 2026-03-18 发布《General Considerations for the Use of New Approach Methodologies in Drug Development》指南草案，确立 COU / 人类生物学相关性 / 技术表征 / fit-for-purpose 四原则；欧盟委员会 2026-06-01 发布化学品安全评估动物试验淘汰路线图（C(2026)3497）；EMA 2026-03 就虚拟对照组资格认定征求意见。ICH 层面尚无类器官专门指南——这是行业最大的制度性不确定性。 7.2 玩家格局：胶质瘤专属商业化仍然稀缺主体类型胶质瘤相关度可核验动态HUB Organoid Technology （荷兰） PDO 模型库 / CRO 泛瘤种（含脑癌） 1,500+ 模型库；2024/2025-01 被 Merck KGaA 完成收购；分层收费（基础药敏 vs 高端 PDXO 建模）冠科生物 Crown Bioscience （JSR 生命科学集团） CRO 泛瘤种取得 HUB 全套技术商用授权，共建荷兰乌得勒支联合实验室，搭建 OrganoidXplore 平台；约 1,000 个 HUB 赋能类器官模型，覆盖 35 种适应症；苏州实验室 2025 年 10 月获 CLIA 认证；2026-04 与 Turbine 合作（AI 靶点预测 + 类器官实体验证）Cellesce （英国） PDO 规模化生产泛瘤种 2022-12 被丹纳赫 Molecular Devices 收购；周产能 10,000 类器官Samsung Biologics （韩国）类器官 CRO 泛瘤种已推出类器官平台，活检→药敏报告周期压缩至 21 天DKFZ / 上海科技大学 IPTO 项目学术 → spin-off胶质瘤强相关已成立 DKFZ spin-off 推进药物测试；目标为「多组学 + AI 个体化推荐」首都医科大学天坛医院 GlioME （江涛院士 / 保肇实教授）医院主导胶质瘤强相关保留原生免疫微环境；个案实现类器官指导用药并达 RANO 2.0 CR首都医科大学张力伟团队 BSGO 医院主导胶质瘤强相关 54/59 = 91.5%，含鞘内三联治疗（TIT）方案发现国内泛瘤种平台（科途医学、创芯国际、丹望医疗、大橡科技、艾名医学、基石生命、耀速科技等）试剂/CRO/设备泛瘤种，胶质瘤非主攻各类公开动态均集中在泛瘤种药敏、器官芯片、自动化设备与 AI 方向一句必须写进尽调纪要的话：胶质瘤类器官目前最接近转化的成果全部来自「学术/医院 → spin-off 或院内平台」，尚未检索到公开的、胶质瘤专属的规模化商业报价与批量交付案例。任何声称已有「胶质瘤类器官标准化商业产品线」的说法，都应要求对方提供株数、取材通道构成、成功定义三项证据——这正是本系列第 03、04 期确立的「建立率四要素」引用纪律。 7.3 场景优先级与客户药企 HTS（最优先） 8 天内完成 166 药筛选的流水线已跑通，买方是神经肿瘤管线药企与 CRO；临床药敏（政策刚落地）医保立项已通，买方是三级医院神经外科/检验科，报告周期 2–4 周是竞争焦点；模型授权（中长期） GBO 株库按亚型分组授权，须先解决第 4 节的亚型认证问题； IO 共培养 / 电场治疗评价（前沿） TTFields 的体外敏感性尚无明确预测标志物，200 kHz 电场下肿瘤球形成抑制率 >50% 是当前唯一的体外判读线索（行业口径，须自建验证，不可直接引用为客户承诺）。八、风险与红线清单类别风险规避动作技术取材超窗（>3 h 或解剖 >2 h）导致活力断崖术前获取排台信息、派员进手术室；建库份与病理份同时分装技术坏死区混入拉低成球率按 npj 2026 纪律只取增强区、避坏死；导航取样 SOP 写死，不接受技术员裁量技术亚型漂移（少突→星形、GBM 转录态漂移）建库时即做 1p/19q + IDH 双锚定；每 10–15 代复测分子锚与转录态技术建立率口径混淆（GSC 培养 96% ≠ 类器官）对外材料严格区分「GSC 培养 / organoid」两类资产；报数必须附「取材通道 × 培养基版本 × 成功定义 × 样本量」四要素技术未建成亚型被误排入产品线毛细胞型星形细胞瘤、SEGA、ATRT、间变性脑膜瘤、前庭神经鞘瘤一律标注「研究性建模」技术复发样本 20%–30% 培养失败率临床承诺写「建库成功后 X 天出报告」，不写「送样后 X 天」合规人遗：胶质瘤基因数据（WES / scRNA-seq / 甲基化）属人类遗传资源信息对齐《人类遗传资源管理条例》（2024-03-10 修订，主管部门已由科技部调整为国家卫生健康委）与《实施细则》（科技部令第 21 号）；采集/保藏/对外提供均须审批或报告合规外方合作（如中德 IPTO 模式）境外主体及其实际控制的境内主体均可能构成外方单位；外方单位不得在境内采集、保藏我国人类遗传资源，不得向境外提供；须走国际科学研究合作行政许可或国际合作临床试验备案合规人遗信息出境对外提供/开放使用须事先向国家卫健委报告并提交信息备份；人数 >500 例的外显子组/基因组测序资源须经安全审查合规脑类器官伦理 2025-05《人源类器官研究伦理指引》对复杂脑类器官的意识属性风险提出检测要求；iPSC 脑类器官 + 人肿瘤体系属高敏感类别，须单独说明意识/痛觉风险的检测与限制合规知情同意术中冗余组织采集须在手术知情同意中设单独条款；复发患者二次取材须重新取得同意；脑组织样本的用途边界（是否可用于基因数据、是否可用于外方合作）须逐项勾选质控无抗生素悬浮培养的污染风险两性霉素 B 常规加入；支原体每 4–8 周复检；建立批次污染归档追溯质控代次过深 >P10 须复测 TMZ IC50 与亚型锚；冻存-复苏株须重做 SNV 重叠（实测 88.4%）质控「重聚球」冒充「原位类器官」单细胞重聚球直径缩小 ≥60%（npj 2026），仍可作为药敏资产，但不得声称保留了原位组织结构与微环境；微环境声明只能由 GlioME/ALI 类路线发出本篇判断该不该投产：该，但只投两条线，且必须与神外手术室绑定。纯悬浮 GBO 线（产量 + 药企 HTS）按 61%–63% 的稳定建立率立项，预设 66.7% 门槛。核心资产是「可传代 GBO 株库 + 8 天 166 药筛选流水线」，卖方是神经肿瘤管线药企与 CRO。建议投产。 GlioME / ALI 线（临床药敏 + 免疫场景） 88.2% 建立率 + 原生免疫保留是胶质瘤唯一可与上皮瘤种拉开差距的差异化资产，且直接对接已打通的医保立项与电场治疗评价需求。建议以合作研发方式优先投产（与有天坛/华山级别神外中心的医院共建），不要自建。不建议投产：IDH 突变低级别（生长过慢，回收周期长）、儿童低级别（毛细胞型/SEGA 无模型）、ATRT、脑转移（属独立产品线）。投资优先级亚型认证能力 > 建立率 > 通量。胶质瘤的建立率天花板已经清楚（61%–63% 悬浮 / 88.2% ALI），任何团队再往上挤 10 个百分点的边际价值，都低于「把 1p/19q + IDH + MGMT + H3K27M 四个锚打进每一株的放行标准」。一句话风险定价胶质瘤类器官的护城河不在实验室，在手术室的 3 小时。能拿到导航定点取材的人，才有产能；拿不到的人，只能在病理科门口等剩下的标本。来源与数据说明建立率数据（第 4 节）：GBO 悬浮 61.0%（55 例/59 样本 → 36 株，成功定义=建成可传代株）来自 Cell Reports Medicine 2026-06-12（KAIST / 忠南大学医院，DOI 见文献库）；63.3% 来自 Neuro-Oncology 2025 Vol.27 Suppl.5 TMOD-07（28 例/30 样本 → 19 株，DOI 10.1093/neuonc/noaf201）；前瞻注册预设 66.7% 来自 ClinicalTrials.gov NCT06782984（研究期 2021-08-18 起，预计 2028-12 完成，目标 100 株/150 例）。73%→83%（15/18）来自 FASEB 期刊系 DOI 10.1002/cns.71024（改良法，成功定义=可传代/冻存/复苏）。88.2% 来自 Bioactive Materials 2025;53:205-217（GlioME，DOI 10.1016/j.bioactmat.2025.07.015）。91.5%（54/59）来自 Cell Stem Cell 2026-09-16（首都医科大学张力伟团队 BSGO；同期摘要亦见 Neuro-Oncology Pediatrics 2026 Suppl）。96% 为 PMC12116786 报告的 GSC 培养建立率（114 例连续 HGG 标本，手术切除 + 超声吸引，SCD + 3DD 双路），非类器官建立率，本文明示区分。血清-free 患者来源培养报道成功率 30%–70% 为 PMC12116786 引言汇总口径。分子分型依据：WHO CNS5（2021）中枢神经系统肿瘤分类；GBM 转录亚型沿用 Verhaak 2010 三分类与 Neftel 2019 四态框架。药敏一致性数据：100% / 77.8% / p<0.05 来自 Cell Reports Medicine 2026-06-12；p=0.011 来自 SNO 2025 TMOD-07；IPTO 35 例前瞻队列来自 Cell Stem Cell 2025（Peng 等）；AI4Med 97%/85% 来自 ASCO 2026，JCO 2026;44(16_suppl):e14086；TMZ AUC 200–600 区间为 Golebwska 团队口径（经《协和医学杂志》综述转述，建议回溯原文）；8 Gy γ 照射数据来自 Current Medicinal Chemistry 2026；蛋白酶体/HDAC 抑制剂与 166 药 HTS 来自 npj Precision Oncology 2026;10(1):228（DOI 10.1038/s41698-026-01552-5）。GlioME 的 vebreltinib 案例为 n=1 个案，本文已显式标注，不得作为一致性率引用。流行病学口径：年发病率 5–8/10 万来自新华网 2025-09-29（华山医院口径）；5.8/10 万（95% CI 5.2–6.4）为中国脑肿瘤登记中心口径。GBM 占颅内原发恶性肿瘤 45.2% 为 2025 年行业口径（再鼎医药支持的医患分享会/环球网 2025-07-15），另一「>50%」表述分母不同，本文并列标注。5 年生存率三口径（<5% / <7% / <10%）来源不同，本文不取单一数字。IDH1/2 突变率 47%–53% 来自新华网 2025-09-29。儿童胶质瘤年新增 8,000–10,000 例为 2025 年国家癌症中心口径（经第三方转述，建议回溯年报原文）。DMG 0.06/10 万来自 CBTRUS，占中国 CNS 肿瘤 1.01% 来自 NBTRC。治疗端动态：EF-14 长期随访（中位 OS 20.9 vs 16.0 个月，5 年 13% vs 5%）为已发表数据；国产电场治疗 ASVir-G3（天坛医院牵头 11 家医院，mOS 31.11 个月、mPFS 12.91 个月）及 2025-12 NMPA 获批来自央广网 2025-12-29 报道；IDH 双靶点抑制剂经《临床急需药品临时进口工作方案》在华山医院落地来自新华网 2025-09-29。上述为企业与媒体披露口径，正式临床数据以官方公告与期刊原文为准。监管进展：CDE 类器官监管时间线（2021-11 起）、2026-07-07「先锋计划」申报通知与 2026-09-28 正式发布（通告 2026 年第 46 号）、2026-08-31 单抗减替指导原则征求意见稿，均引自 CDE 官网及行业解读（丹望医疗 2026-09-30、傲睿科技行业梳理）。2026-08-14 国家医保局《检验类医疗服务价格项目立项指南（试行）》纳入「肿瘤组织类器官培养费」与「肿瘤类器官药物敏感性检测费」及其计价规则（每例标本·每种药物；缺数减收 ≥10%、上限 5 元），引自国家医保局发布及行业解读。FDA 2026-03-18 NAMs 指南草案四原则、EU C(2026)3497、EMA 2026-03 虚拟对照组征求意见为公开文件。「先锋计划」实施细则与各省价格基准以官方发布为准。企业与市场数据：HUB 被 Merck KGaA 收购（2025-01 完成，官方公告）、冠科生物 HUB 授权与约 1,000 个类器官模型/35 种适应症/苏州实验室 2025-10 CLIA 认证（企业官方新闻稿与腾讯新闻转载）、Cellesce 被 Molecular Devices 收购、QGel 与 Samsung Biologics 定价（第三方市场研究报告口径，未经审计，引用时须标注「以官方公告为准」）。国内企业动态引自公开行业梳理（2026-09 类器官企业盘点、艾名医学访谈、基石生命资料）。本文未编造任何公司名或数据。合规依据：《中华人民共和国人类遗传资源管理条例》（2019 国务院令第 717 号，2024-03-10《国务院关于修改和废止部分行政法规的决定》修订，主管部门由国务院科学技术行政部门调整为国家卫生健康委）；《人类遗传资源管理条例实施细则》（科技部令第 21 号，2023-05-26）；国家卫健委科教司《人类遗传资源管理常见问题解答》（2025-03-27）；2026-05-08《实施细则》征求意见稿（采集行政许可门槛由 3,000 例提高至 10,000 例）；安全审查情形含人数 >500 例的外显子组/基因组测序资源。伦理依据：《人源类器官研究伦理指引》（2025-05）；《生物医学新技术临床研究和临床转化应用管理条例》（国务院令第 818 号，2026-05 施行）。区域表述：中国香港 / 中国澳门 / 中国台湾。本文所有建立率均写成「瘤种 × 取材方式 × 培养基版本 × 成功定义 × 样本量」的条件组合，未给出任何无条件的单一数字。本文完｜上下两期合为一篇完整的瘤种分析，未做删减。

ASCO会议临床1期临床结果申请上市

2026-10-15

·脑医汇-神外资讯

【风向标｜药械】NanO₂氧疗平台获FDA快速通道资格，卒中及胶质母细胞瘤II期研究同步推进中

急性缺血性卒中（AIS）是全球致死和致残的主要原因之一。其病理核心在于大血管闭塞导致脑组织血流中断，引发局部缺血缺氧，脑细胞在数分钟内即开始不可逆损伤。尽管机械取栓和静脉溶栓等再灌注治疗已显著改善部分患者预后，但严格的时间窗限制使大量患者无法及时接受治疗，或因血管解剖复杂、再通失败等原因无法实现有效血流恢复。即使在成功再通的患者中，缺血半暗带在再灌注前的持续缺氧仍会扩大最终梗死体积，直接影响神经功能恢复。美国生物制药公司NuvOx推出的NanO₂（活性成分：十二氟戊烷乳剂）是一种新型静脉用氧载体，利用全氟化碳的高溶氧特性，在生理温度下高效释放氧，旨在改善从血液到组织的氧运输。在卒中场景中，NanO₂通过维持半暗带区域的氧供，延长神经元的存活时间，为再灌注治疗争取宝贵窗口，并可能减少最终梗死体积。动物研究和既往IIa期临床试验已提示其神经保护潜力。 2025年1月21日，英国大格拉斯哥和克莱德地区国家医疗服务体系（NHS Greater Glasgow and Clyde）牵头开展了NanO₂治疗大血管闭塞（LVO）所致急性缺血性卒中的NOVEL研究（NanO₂ in Large VessEL Occlusion Stroke）。该研究是一项多中心、随机、安慰剂对照、盲法终点设计的IIb期研究。计划入组172例患者，在标准再灌注治疗基础上随机接受NanO₂或安慰剂。主要终点为24小时影像学（弥散加权MRI或非增强CT）评估的半暗带挽救体积，关键次要终点包括神经功能缺损（NIHSS）、残疾程度（改良Rankin量表）和安全性。 2026年7月15日，美国食品药品监督管理局（FDA）正式授予NanO₂治疗急性缺血性卒中成人患者的快速通道资格。 NuvOx Therapeutics总裁兼首席执行官Rong Wang表示，“我们很荣幸FDA认可了NanO₂在解决急性卒中治疗中最大未满足医疗需求之一的潜力，快速通道资格是一个重要的里程碑。我们相信，这验证了我们氧治疗平台的目标，并支持我们加快NanO₂临床开发的承诺，以造福迫切需要新治疗选择的患者。我们期待在推进卒中项目过程中与FDA密切合作。” NuvOx Therapeutics董事会执行主席兼联合创始人Evan C. Unger表示，“这一资格认定是对NanO₂背后科学原理潜力的重要认可。多年来，我们的团队一直致力于开发一种能够向尚存活力但严重缺氧的组织递送氧气的疗法。我们相信，这项技术有潜力从根本上改变缺血性疾病的治疗模式，从急性卒中开始。” 除卒中外，NanO₂在肿瘤领域亦取得重要进展。2025年9月，针对新诊断胶质母细胞瘤的IIb期RESTORE研究完成全部87例患者给药，以评估NanO₂作为放射增敏剂联合标准放化疗的效果。2026年3月，FDA授权启动针对复发性高级别胶质瘤的REBORN II期研究，计划对66例受试患者，联合贝伐珠单抗、洛莫司汀和放疗，以进一步探索其改善肿瘤氧合、增强放疗敏感性的潜力。关于NuvOx Therapeutics 总部位于美国亚利桑那州图森市的NuvOx（https://www.nuvoxtherapeutics.com/）是一家私营临床阶段生物制药公司，致力于开发新型氧疗法平台，用于治疗因组织缺氧而恶化的各类疾病。公司的候选产品NanO₂目前已完成两项Ib/II期研究：一项针对胶质母细胞瘤，作为放射增敏剂；另一项针对卒中，作为神经保护剂。该产品已在7种以上适应症的临床前和临床各阶段积累了安全性和有效性数据，并已获得胶质母细胞瘤和镰状细胞贫血的孤儿药资格认定。长按识别左侧二维码进入风向标专栏查看更多精彩文章声明：脑医汇旗下神外资讯、神介资讯、脑医咨询、AiBrain所发表内容之知识产权为脑医汇及主办方、原作者等相关权利人所有。未经许可，禁止进行转载、摘编、复制、裁切、录制等。经许可授权使用，亦须注明来源。欢迎转发、分享。投稿/会议发布，请联系400-888-2526转3 脑医汇App全新功能“AI问答”正式上线，您临床实践中的得力助手！欢迎点击“阅读原文”了解更多！点分享点收藏点点赞点在看

2026-10-14

·PRNewswire

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026. Dr. David N. Cade, Telix Group Chief Medical Officer, said, "Our expansive presence at EANM reflects the breadth and maturity of Telix's pipeline, spanning pivotal therapeutic studies, precision diagnostics and next-generation technologies. The selection of 12 abstracts for top-rated oral presentations is a strong recognition of the quality and clinical relevance of this work. We look forward to continuing this discussion at our sponsored symposium on the future of theranostics in urologic oncology." Key presentations include the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in ccRCC, and interim results from the PTherpan-Lu trial of TLX597-Tx in mAPMR prostate cancer[1]. Topline Phase 3 data for TLX591-Px (Illuccix) PET[2] imaging of prostate cancer in Chinese men will also be presented, together with real-world experience with TLX250-Px (Zircaix[3]) in ccRCC, and research from our targeted alpha therapy and MedTech programs. As in previous years, Telix will support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and inspiring educator. Visit booth #527 to explore opportunities for collaboration with Illuccix® (kit for the preparation of gallium-68 gozetotide injection), Telix's commercial PSMA-PET imaging[4] agent in Europe; our theranostic pipeline; and our medical technologies, including the SENSEI® miniature drop-in gamma probe, QDOSE® dosimetry software and artificial intelligence (AI). EANM presentation details are as follows (all times CEST): Sponsored Symposium Title: The future doesn't wait: The next era of theranostics in urologic oncology. Date & Time: 18-Oct-26, 13:15 – 14:45 Location: Hall F2, Austria Center Vienna Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France Agenda: The theranostic revolution J. Calais The evolving role of PSMA-PET in prostate cancer K. Herrmann, University Hospital Essen, Germany M. Ghesani, United Theranostics, USA Next-generation PSMA therapeutics: Overcoming today's challenges D. Oprea-Lager, Radboud University Medical Center, Nijmegen, the Netherlands L. Emmett, St Vincent's Hospital, Sydney, Australia Panel discussion - all Extending prostate cancer theranostic success to broader GU diseases J. Calais Oral presentations Title: ELEGANCE, Prospective pilot study, assessing imaging performance of TLX250-Px ([⁸⁹Zr]Zr-girentuximab) PET/CT in Patients with Hepatocellular Carcinoma, Biliary Tract Cancer or Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (NCT06735560) Date and Time: 18-Oct-26, 08:00 – 09:30 Presenter: Clement Bailly, CHU Nantes Abstract #: OP-036 Title: HIMIKO, TLX591-Px ([⁶⁸Ga]Ga-PSMA) PET/CT in Hepatocellular Carcinoma: impact of Multiparametric dynamic whole-body imaging and kinetic modelling (NCT06999837) Date and Time: 18-Oct-26, 08:00 – 09:30 Presenter: Rachel Bardy, CHU Nantes Abstract #: OP-041 Title: Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px ([⁸⁹Zr]Zr-girentuximab) in Von Hippel-Lindau Disease: preliminary results from the CAT-VHL Phase 2 trial (NCT07171905) Date and Time: 18-Oct-26, 15:00 – 16:30 Presenter: Fabrizia Gelardi, San Raffaele Hospital Abstract #: OP-168 Title: LUTEON, Phase 3 study to assess safety and efficacy of TLX250-Tx (¹⁷⁷Lu-girentuximab) in advanced, relapsed or recurrent ccRCC (NCT07197580) Date and Time: 18-Oct-26, 15:00 – 16:30 Presenter: Ghoufrane Tlili, CHU Bordeaux Abstract #: OP-170 Title: Building the traceability backbone for radiopharmaceutical therapy, first results from the PDIB Secondary Standards Laboratory Network Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Steven Graves, University of Iowa Abstract #: OP-291 Title: Optimizing SPECT/CT for alpha emitters: Phantom validation and calibration of [²¹¹At] imaging Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Rob van Rooij, UMC Utrecht Abstract #: OP-294 Title: IODO-RISE, TLX101-Tx (iodofalan-¹³¹I) in recurrent high-grade glioma, investigation of safety and efficacy Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Tim Sturre, UMC Utrecht Abstract #: OP-311 Title: IPAX BrIGHT, Pivotal study of TLX101-Tx (iodofalan-¹³¹I) with or without lomustine vs lomustine alone for the treatment of patients with radiographically confirmed recurrent glioblastoma at first recurrence (NCT07100730) Date and Time: 19-Oct-26, 08:00 – 09:30 Presenter: Nelleke Tolboom, UMC Utrecht Abstract #: OP-312 Title: Comparative evaluation of TLX252-Tx ([²²⁵Ac]Ac-) and TLX250-Tx ([¹⁷⁷Lu]Lu-DOTA-hG250) targeted radionuclide therapy and combination with PD1 blockade in a preclinical renal cell carcinoma model Date and Time: 19-Oct-26, 16:45 – 18:15 Presenter: Twan van der Werff, UMC Radboud Abstract #: OP-478 Title: Interim results from PTherpan-Lu trial: TLX597-Tx ([¹⁷⁷Lu]Lu-panPSMA) radionuclide therapy for patients with mCRPC[5] Date and Time: 19-Oct-26, 16:45 – 18:15 Presenter: Yehia Omar, Misr Radiology Abstract #: OP-523 Title: Integration of spatial analysis and deep learning for enhanced tumor classification in total-body PET/CT imaging: using residual deep learning with spatial feature augmentation and cross-validated ensemble learning Date and Time: 20-Oct-26, 09:45 – 11:15 Presenter: Simon Wail, Telix Pharmaceuticals Abstract #: OP-613 Title: TLX250-Px ([⁸⁹Zr]Zr-girentuximab) PET/CT for characterization of indeterminate renal masses, diagnostic performance and clinical impact in a real-world cohort Date and Time: 20-Oct-26, 09:45 – 11:15 Presenter: Sazan Rasul, Medical University of Vienna Abstract #: OP-627 ePosters Title: QDOSE® allometry-guided human dosimetry of TLX102-Tx ([²¹¹At]APA): Impact of administration route on maximum tolerated activity Abstract #: EP-0067 Title: Illuccix China, preliminary results from Phase 3 trial of TLX591-Px (⁶⁸Ga-PSMA-11) PET for detection of biochemical recurrence of prostate cancer in Chinese men (NCT05847348) Abstract #: EP-0460 Title: TLX250-Px (⁸⁹Zr-girentuximab) PET/CT in Von Hippel Lindau disease; initial real-world experience in VHL expert center Abstract #: EP-0595 Title: TLX250-Px (⁸⁹Zr-girentuximab) PET/CT in clear cell renal cell carcinoma, impact on staging and clinical management Abstract #: EP-0599 Title: Impact of TLX250-Px (⁸⁹Zr-girentuximab) based radionuclide imaging in patients with renal cell carcinoma on virtual tumor board decision making Abstract #: EP-0606 Title: A semi-mechanistic population biodistribution model of TLX250-Px (⁸⁹zr-girentuximab) for the diagnosis of clear cell renal cell carcinoma Abstract #: EP-0999 Title: Potential for radioguided surgery based on internal conversion electron detection using a compact CMOS detector Abstract #: EP-1070 Title: A dosimetric study of bladder endocavitary therapy using astatine-211 Abstract #: EP-1239 About Telix Pharmaceuticals Limited Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan 131I) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit or follow Telix on LinkedIn,X and Facebook. Investor Relations Annie Kasparian [email protected] Charlene Jaw [email protected] Media Eliza Schleifstein 917.763.8106 (Mobile) [email protected] Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2026 Telix Pharmaceuticals Limited. All rights reserved. 21% more press release views with Request a Demo

临床3期临床结果临床2期上市批准

100 项与洛莫司汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00363	洛莫司汀	L01AD02	DB01206

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
支气管癌	中国	南京制药厂有限公司	1982-01-01
胶质瘤	中国	南京制药厂有限公司	1982-01-01
淋巴瘤	中国	南京制药厂有限公司	1982-01-01
直肠癌	中国	南京制药厂有限公司	1982-01-01
胃癌	中国	南京制药厂有限公司	1982-01-01
脑癌	美国	Azurity Pharmaceuticals, Inc.	1976-08-04
霍奇金淋巴瘤	美国	Azurity Pharmaceuticals, Inc.	1976-08-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANO2026	N/A	高级别胶质瘤	214	Lomustine 90 mg/m2	衊憲遞餘夢夢艱製網蓋(積艱憲顧鏇觸鹽艱積壓) = 製蓋衊憲積壓範鑰遞簾膚壓鬱製鹹糧廠願範淵 (糧醖製醖選選獵顧積獵, 2.7 ~ 4.1) 更多	积极	2026-09-24
				Lomustine 110 mg/m2	衊憲遞餘夢夢艱製網蓋(積艱憲顧鏇觸鹽艱積壓) = 鏇範糧願醖願鹽網觸觸膚壓鬱製鹹糧廠願範淵 (糧醖製醖選選獵顧積獵, 2.6 ~ 4.1) 更多
EANO2026	N/A	胶质母细胞瘤	152	Bevacizumab-Irinotecan	窪襯鬱壓膚齋鹹觸網積(醖選築憲衊窪襯鏇淵憲) = 積艱構築壓製醖網簾範鹽夢簾鏇鬱壓鬱鬱鏇遞 (艱鏇壓襯衊齋網繭艱顧 ) 更多	积极	2026-09-24
				Bevacizumab-Lomustine	窪襯鬱壓膚齋鹹觸網積(醖選築憲衊窪襯鏇淵憲) = 淵糧製襯餘範鑰觸艱餘鹽夢簾鏇鬱壓鬱鬱鏇遞 (艱鏇壓襯衊齋網繭艱顧 ) 更多
NCT07100730 (IPAX-BrIGHT, EANO2026)	临床2期	复发性胶质母细胞瘤	68	Iodofalan (131I) + Lomustine	蓋繭襯鏇齋鹽鏇襯選淵(構製願夢鏇簾艱鬱繭糧) = 願願鑰淵鹹築蓋蓋蓋鏇顧鹽構選壓網壓餘顧製 (築窪範獵襯鏇範艱憲觸 )	积极	2026-09-24
EANO2026	N/A	星形细胞瘤一线 BRAF V600E	18	Radiochemotherapy with concurrent and adjuvant temozolomide (TMZ)	壓齋積製壓膚獵製簾選(積憲襯鏇廠淵醖觸憲壓) = 簾獵獵鹹鏇築鑰鹹構繭糧膚淵遞膚艱鑰蓋窪糧 (糧製築淵鏇選壓艱夢襯 ) 更多	积极	2026-09-24
AAN2026	N/A	多形性胶质母细胞瘤 MGMT promoter methylation	793	CCNU-based regimens	鑰顧製夢構積遞築衊襯(範觸積醖選糧淵網遞醖): HR = 0.88 (95.0% CI, 0.6 ~ 1.29), P-Value = 0.52 更多	积极	2026-04-25
				Temozolomide-based regimens
CeTeG/NOA-09 (EANO2024)	临床3期	胶质母细胞瘤	31	Lomustine-Temozolomide Chemotherapy + Radiotherapy	餘鏇鑰淵繭選築獵簾遞(醖衊願範獵醖壓艱憲鏇) = 鹹網襯鬱淵廠網蓋鏇壓網窪窪齋壓膚醖窪廠製 (蓋簾艱餘蓋觸簾餘簾鑰 )	积极	2024-10-17
CeTeG/NOA-09 (EANO2024)	N/A	胶质母细胞瘤 MGMT-methylated \| IDH-wildtype	17	CCNU/TMZ	衊淵膚鏇蓋網鹽築壓襯(襯簾積衊網鹽鬱範憲選) = 夢鬱製艱醖築窪衊鏇鏇鬱範糧繭遞鏇憲糧觸衊 (壓壓築網製選願窪簾餘, 17.6 ~ not reached) 更多	积极	2024-10-17
CTRI/2020/07/026696 (VAMANA, ASCO2024) 人工标引	临床2期	胶质母细胞瘤	46	bevacizumab+CCNU	築餘遞壓觸膚壓積壓構(遞鹹鏇衊鹹餘鹽選膚襯) = 壓憲憲衊鹹襯夢鑰憲範製網醖鹹醖鏇膚製獵顧 (夢製醖淵簾築襯鹹齋壓, 5.474 ~ 6.793) 更多	积极	2024-06-02
EORTC 26101 (SNO2022)	临床2/3期	复发性胶质母细胞瘤	-	Lomustine alone	糧鏇衊窪鑰廠憲觸積鏇(衊窪憲糧繭積顧構遞衊) = Thrombocytopenia represents the main cause of stopping chemotherapy for toxicity during the treatment of glioblastoma 網艱膚齋網醖鑰築衊願 (壓鬱鹽鏇遞膚範顧範膚 ) 更多	不佳	2022-11-14
				Lomustine plus bevacizumab
PROTECT (SNO2022)	N/A	低级神经胶质瘤辅助 1p/19q co-deletion	20	Procarbazine, Lomustine, Vincristine (PCV)	憲襯鏇範艱網製憲觸觸(醖簾範獵鑰蓋壓鬱製獵) = 鑰壓積築壓糧餘簾齋遞遞窪膚憲憲蓋簾艱鏇膚 (淵襯製築糧繭壓鏇鑰夢 ) 更多	不佳	2022-11-14
				Temozolomide (TMZ)	憲襯鏇範艱網製憲觸觸(醖簾範獵鑰蓋壓鬱製獵) = 簾鹹鑰糧願築襯觸獵鹽遞窪膚憲憲蓋簾艱鏇膚 (淵襯製築糧繭壓鏇鑰夢 ) 更多